PSNL

Personalis Inc. (PSNL) | Rumor.io

Personalis

PSNL

Attention (50-day avg)0%

Attention rank (50-day avg)#685

Bullish sentiment (50-day avg)77%

Price to earnings ratio-18

Market capitalization1.7B

Earnings per share-1.09

Dividend yield (TTM)—

Revenue (annual)69.6M

Net income (annual)-81.3M

Social

What share of all stock conversation is about PSNL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% +0

Aug 25

Personalis, Inc.'s ($PSNL) acquisition by Temos Health Inc. ($TEM) is expected to boost revenue to $4-5B by 2030, assuming a smooth process.
The company's AI utilization in biotech is seen as a technological revolution, and it's one of the biotech stocks with potential for a multibagger in 2025.
$PSNL's stock price may be drifting back to the acquisition price, with no indication of a higher bid, and shorts have left the table.

Generated by AI

Sentiment

Of the messages about PSNL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	97.56% +5.89	97% +26.84	81.75% -9.03
Bearish	0% 0	2.44% -5.89	3% -26.84	18.25% +9.03

Bullish· Aug 19

$PSNL has the potential for significant upside, with multiple scenarios resulting in a substantial increase in its current trading price of under $15/sh.
The company's valuation is "ridiculous" considering its current low price, making it a compelling buy opportunity.
$PSNL's partnership with Moderna and its focus on advanced genomic sequencing and analytics support for cancer vaccines and immunotherapies could lead to a 24+ price target, making it an attractive investment opportunity.

Bearish· Jul 20

The buyout deal between Personalis, Inc. ($PSNL) and Merck has been met with disappointment, with some investors calling it a "worst buyout ever" and expressing frustration with the low price of $16.50 per share.
The deal has been criticized for devaluing Personalis, Inc. stock, with some investors questioning the leadership's decision to sell at such a low price, especially considering the stock's previous triple-digit price target.
The uncertainty surrounding the deal has led to a breakdown in the stock's price, with some investors warning of a potential short-selling opportunity if the price continues to decline below $46.

Generated by AI

Topics

Of the messages about PSNL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	8.05%	31.1%	60.44%
Technical Analysis	—	1.15%	6.3%	23.26%
Analysts	—	45.4%	31.1%	6.71%
Macro	—	45.4%	31.1%	7.24%
Controversies	—	0%	0.39%	0.64%
Earnings	—	0%	0%	1.7%

Analysts· Mar 9

Morgan Stanley has raised Personalis' price target to $38.00.
Analysts are likely to take this into consideration when making investment decisions.
This move may indicate increased confidence in the company's prospects.

Announcements· Jul 20

Tempus AI ($TEM) is acquiring Personalis ($PSNL) for $1.5 billion, adding Personalis' NeXT Personal MRD technology to expand deeper into cancer recurrence monitoring.
Personalis shareholders will receive $16.25 per share, a 6% premium to the latest close and a 28% premium to the unaffected 30-day average.
The acquisition brings together Tempus' multimodal data platform, AI capabilities, and precision oncology portfolio with Personalis' tumor-informed MRD technology, expanding access to longitudinal monitoring and creating new opportunities to advance biomarker discovery and enhance personalized cancer care.

Generated by AI

Community

Of the messages about PSNL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	42.77%	51.81%	63.97%
Newcomers	100%	57.23%	48.19%	36.03%

Regulars· Aug 21

The acquisition of Personalis by Tempus for $1.5 billion has led to a significant increase in the company's valuation, with some shares reaching a new 52-week high.
The deal has also sparked rumors of a potential higher bid, with some investors believing that another company may enter the fray and make its own offer to buy Personalis.
The acquisition has also led to a change in the company's focus, with Tempus planning to handle gene sequencing once the Moderna and Merck personalized cancer vaccine receives FDA approval, enabling Personalis's tools to identify unique markers in a patient's cancer cells.

Newcomers· Aug 20

Newcomers are focusing on the potential deal between Tempus AI and Personalis, with some expecting a positive outcome and others anticipating a potential increase in the bid price.
The recent news about Moderna's cancer vaccine, which was built on Personalis' technology, is being seen as a positive development for the company, with some users expecting a significant increase in the stock price.
There is speculation about the potential for Merck to step in and acquire Personalis, with some users questioning the current valuation and others anticipating a potential class action lawsuit against the company's management.

Generated by AI

News

Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

Personalis shareholders remain exposed to downside in TEM shares while having limited ability to benefit from further TEM appreciation above $48.42. Learn more about PSNL stock here.

2h agoSeeking Alpha

Also Discussed

Investors talking about PSNL also mention

#	Name	Attention
1	Twist Bioscience CorporationTWST	0%-0.02
2	Natera, Inc.NTRA	0%-0.01
3	Guardant Health Inc.GH	0%-0.11
4	TCON - TRACON Pharmaceuticals, Inc.	——
5	OMIC - Singular Genomics Systems, Inc.	——
6	NVTA - Invitae Corporation	——
7	Veracyte, Inc.VCYT	0%new
8	Homology Medicines IncFIXX	0%0
9	GeneDx Holdings Corp. Class A Common StockWGS	0%+0
10	ClearPoint Neuro Inc.CLPT	0.03%+0.02

Personalis Inc.

Healthcare
Diagnostics & Research

Personalis Inc. is a biotechnology company focused on advanced cancer genomics and precision oncology. Personalis develops and markets genomic tests and sequencing services that help healthcare providers, pharmaceutical companies, biopharma partners, universities, and government organizations analyze tumor and immune-system signals. Its current offerings include liquid biopsy and molecular profiling solutions designed to detect minimal residual disease, monitor recurrence, and support therapy selection, along with sequencing and data analysis services for population-scale research programs. The company also provides platforms and assays used in immuno-oncology and personalized cancer vaccine development. Personalis serves customers primarily in the United States and Europe, with additional international reach through research and clinical applications. Headquartered in Fremont, California, Personalis plays an important role in translating complex genomic data into actionable insights for cancer research and patient management.

Website

Location

6600 Dumbarton Circle

Fremont, CA, 94555

United States

Social

What share of all stock conversation is about PSNL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% +0

Aug 25

Personalis, Inc.'s ($PSNL) acquisition by Temos Health Inc. ($TEM) is expected to boost revenue to $4-5B by 2030, assuming a smooth process.
The company's AI utilization in biotech is seen as a technological revolution, and it's one of the biotech stocks with potential for a multibagger in 2025.
$PSNL's stock price may be drifting back to the acquisition price, with no indication of a higher bid, and shorts have left the table.

Generated by AI

Sentiment

Of the messages about PSNL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100% 0	97.56% +5.89	97% +26.84	81.75% -9.03
Bearish	0% 0	2.44% -5.89	3% -26.84	18.25% +9.03

Bullish· Aug 19

$PSNL has the potential for significant upside, with multiple scenarios resulting in a substantial increase in its current trading price of under $15/sh.
The company's valuation is "ridiculous" considering its current low price, making it a compelling buy opportunity.
$PSNL's partnership with Moderna and its focus on advanced genomic sequencing and analytics support for cancer vaccines and immunotherapies could lead to a 24+ price target, making it an attractive investment opportunity.

Bearish· Jul 20

The buyout deal between Personalis, Inc. ($PSNL) and Merck has been met with disappointment, with some investors calling it a "worst buyout ever" and expressing frustration with the low price of $16.50 per share.
The deal has been criticized for devaluing Personalis, Inc. stock, with some investors questioning the leadership's decision to sell at such a low price, especially considering the stock's previous triple-digit price target.
The uncertainty surrounding the deal has led to a breakdown in the stock's price, with some investors warning of a potential short-selling opportunity if the price continues to decline below $46.

Generated by AI

Topics

Of the messages about PSNL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	8.05%	31.1%	60.44%
Technical Analysis	—	1.15%	6.3%	23.26%
Analysts	—	45.4%	31.1%	6.71%
Macro	—	45.4%	31.1%	7.24%
Controversies	—	0%	0.39%	0.64%
Earnings	—	0%	0%	1.7%

Analysts· Mar 9

Morgan Stanley has raised Personalis' price target to $38.00.
Analysts are likely to take this into consideration when making investment decisions.
This move may indicate increased confidence in the company's prospects.

Announcements· Jul 20

Tempus AI ($TEM) is acquiring Personalis ($PSNL) for $1.5 billion, adding Personalis' NeXT Personal MRD technology to expand deeper into cancer recurrence monitoring.
Personalis shareholders will receive $16.25 per share, a 6% premium to the latest close and a 28% premium to the unaffected 30-day average.
The acquisition brings together Tempus' multimodal data platform, AI capabilities, and precision oncology portfolio with Personalis' tumor-informed MRD technology, expanding access to longitudinal monitoring and creating new opportunities to advance biomarker discovery and enhance personalized cancer care.

Generated by AI

Community

Of the messages about PSNL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	42.77%	51.81%	63.97%
Newcomers	100%	57.23%	48.19%	36.03%

Regulars· Aug 21

The acquisition of Personalis by Tempus for $1.5 billion has led to a significant increase in the company's valuation, with some shares reaching a new 52-week high.
The deal has also sparked rumors of a potential higher bid, with some investors believing that another company may enter the fray and make its own offer to buy Personalis.
The acquisition has also led to a change in the company's focus, with Tempus planning to handle gene sequencing once the Moderna and Merck personalized cancer vaccine receives FDA approval, enabling Personalis's tools to identify unique markers in a patient's cancer cells.

Newcomers· Aug 20

Newcomers are focusing on the potential deal between Tempus AI and Personalis, with some expecting a positive outcome and others anticipating a potential increase in the bid price.
The recent news about Moderna's cancer vaccine, which was built on Personalis' technology, is being seen as a positive development for the company, with some users expecting a significant increase in the stock price.
There is speculation about the potential for Merck to step in and acquire Personalis, with some users questioning the current valuation and others anticipating a potential class action lawsuit against the company's management.

Generated by AI

Personalis

Social

Aug 25

Bullish· Aug 19

Bearish· Jul 20

Analysts· Mar 9

Announcements· Jul 20

Regulars· Aug 21

Newcomers· Aug 20

Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

Personalis SVP, chief legal officer Stephen Moore sells $33,542 in shares

Personalis CFO and COO Aaron Tachibana sells $47,540 in stock

Personalis president & CMO Chen sells $64,847 of PSNL stock

Personalis CEO Christopher Hall sells $120,984 in company stock

The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.

Also Discussed

Personalis Inc.

Company Information

Location

Personalis: The Wrong Side Of The Merger (NASDAQ:PSNL)

Personalis SVP, chief legal officer Stephen Moore sells $33,542 in shares

Personalis CFO and COO Aaron Tachibana sells $47,540 in stock

Personalis president & CMO Chen sells $64,847 of PSNL stock

Personalis CEO Christopher Hall sells $120,984 in company stock

The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.

Also Discussed

Social

Aug 25

Bullish· Aug 19

Bearish· Jul 20

Analysts· Mar 9

Announcements· Jul 20

Regulars· Aug 21

Newcomers· Aug 20